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Abstract
Background: Complementary and alternative medicine (CAM) is a rather novel issue within public healthcare and
health policy-making. CAM use in Europe is widespread, patient-initiated, and patient-evaluated, and the regulation
across countries has been evaluated as disharmonized. CAM users are left in an uncertain position, and patient
safety may be threatened. How “risk” is understood by individuals in health policy-making and clinical encounters
involving the use of CAM has not yet been much debated. The aim of this article is to explore and discuss the
existence and possible consequences of differing risk understandings among stakeholders maneuvering in the
complex landscape of CAM practice and CAM regulation contextualized by European public healthcare systems.
Methods: Qualitative data were derived from two studies on CAM in European healthcare contexts. Findings from the
EU project CAMbrella on legislation and regulation of CAM were mixed with data from an interview study exploring
risk understandings, communication, and decision-making among Scandinavian CAM users and their doctors. In a
secondary content analysis, we constructed the case Sara as a typology to demonstrate important findings with regard
to risk understandings and patient safety involving European citizens’ use of CAM in differing contexts.
Results: By combining and comparing individual and structural perspectives on risk and CAM use, we revealed
underexplored gaps in risk understandings among individuals involved in European CAM regulation and legislation,
and between CAM users and their medical doctors. This may cause health risks and uncertainties associated with CAM
use and regulation. It may also negatively influence doctor-CAM user communication and CAM users’ trust in and use
of public healthcare.
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Conclusion: Acknowledging implications of stakeholders’ differing risk understandings related to CAM use and
regulation may positively influence patient safety in European healthcare. Definitions of the concept of risk should
include the factors uncertainty and subjectivity to grasp the full picture of possible risks associated with the use of
CAM. To transform the findings of this study into practical settings, we introduce sets of questions relevant to
operationalize the important question “What is risk?” in health policy-making, clinical encounters and risk research
involving European patients’ use of CAM.
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conventional treatment, Risk definitions, Risk perceptions, Risk understandings: risk behaviors, Patient safety, Quality in
health care, Health policy-making, Decision making, Person-centeredness, Doctor-patient communication, Risk
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Background
There is no agreed definition of the concept of risk in con-
temporary risk research, and various understandings may
have different strengths and weaknesses [1, 2]. Comple-
mentary and alternative medicine (CAM) is a rather novel
field within risk research and health policy-making. What
constitutes CAM varies with a number of factors and con-
texts, and definitions of CAM change over time as the
borders between public healthcare and CAM are con-
stantly changing. The Cochrane Collaboration has defined
CAM as “… a broad domain of healing resources that en-
compasses all health systems, modalities and practices,
and their accompanying theories and beliefs, other than
those intrinsic to the politically dominant health system”
[3], p. 693. Norway is one of very few countries where
CAM is legally defined. The Norwegian Act No. 64 of 27
June 2003 relating to the alternative treatment of disease,
illness, and so forth [4] defines CAM as:
… health related treatment which is practiced outside
the established health services and which is not
practiced by authorized health personnel. However,
treatment practiced within the scope of the established
health services or by authorized health personnel is
also covered by the term alternative treatment when
the methods used are essentially methods that are
used outside the established health services.
Recent studies show a widespread and continuing use of
CAM among European citizens, although prevalence of
use varies greatly by country [5–11]. Reasons for use are
complex, but is often linked to health-related and socio-
demographic determinants such as gender, income and
self-defined health status [11]. In the Scandinavian coun-
tries, for instance, the prevalence of CAM use is higher
among middle-aged women with higher education, and
people with poor self-reported health [12]. CAM users
may be considered deviant and noncompliant because
they challenge the rationality of medical advice [13–15],
and they report a significantly “lower level of confidence
in the efficacy of conventional medicine”than non-users
[16]. However, most CAM users do not leave the public
healthcare system despite negative experiences that
sometimes function as push-factors for their decision to
use CAM [11–14, 17, 18]. They uphold a relationship to
public healthcare, and studies show that most CAM
users want to discuss possible benefits and risks associ-
ated with their CAM use with their conventional health-
care providers [14, 19]. Despite this, an indirect risk
related to CAM use is that as many as 50% of CAM
users actually do not disclose their use of CAM in clin-
ical settings in public healthcare, often because they fear
that raising this issue may negatively affect the patient-
doctor relation [14, 20, 21].
Diverging risk understandings
We know from other fields of risk research that diver-
ging understandings of what risk is exist both between
policy makers, healthcare professionals and the public,
and that this may affect the way risk is handled [1, 2, 22,
23]. Despite the widespread use of CAM, there has so
far been little attention towards the importance of pos-
sible differing risk understandings among stakeholders.
This may influence decision-making and patient safety
in this field of European healthcare. A main question in
ongoing debates about risk understandings within other
fields of risk research is whether the concept of risk can
escape an element of subjectivity. In other words, can
risk be considered as an ontological, objective fact to be
measured and explained, or not [1, 2, 22, 23]? Based on
the debate in central scientific risk journals, a hermen-
eutic understanding of risk as a social construct has
been introduced as a supplement to the traditionally
dominant understanding of risk as an objective fact that
we also recognize in conventional health care settings.
CAM users experience benefits from CAM that seem to
elude the evidence of efficacy and risk factors generated
in RCT research in their decision-making processes
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[24–26]. The central risk researchers Aven, Renn, and
Rosa [27] in 2011 identified two prevailing definitions of
risk that we find to be a relevant approach to risk under-
standings related to CAM regulation, risk communica-
tion in clinical settings, and European CAM users’
decision-making:
(i) Risk is a situation or event where something of
human value (including humans themselves) is at
stake and where the outcome is uncertain
(ii) Risk is an uncertain consequence of an event or an
activity with respect to something that humans
value ([27], p., 1074)
In this perspective, risk does include uncertainty and
subjective elements, factors that have been identified as
important in understanding modern patients’ use of
CAM [24–26, 28, 29]. Risk understandings among differ-
ent individuals in the field of CAM may be interpreted
based on a variety of contextual factors involving indi-
vidual experience, cultural beliefs, social practices, atti-
tudes, and values.
Research initiatives leading to this paper
The authors of this article have previously conducted two
different qualitative studies where information on such
various risk understandings associated with the use of
CAM in Europe turned out to be important empirical pat-
terns. A study among Scandinavian CAM users and their
physicians in public healthcare revealed rather fundamen-
tal gaps in risk understandings. These gaps were found to
influence decision-making and communication in ways
that may negatively influence patient safety for CAM
users who are also patients in Scandinavian public health-
care systems [14, 15, 28, 29]. The EU-study CAMbrella,
dealing with legislation and regulation of CAM in 39
European countries, revealed no harmony in legislation,
regulation, CAM definitions, terminology, treatments,
providers’ skills or regulatory systems across the 39 coun-
tries. On a structural level, comparable CAM profes-
sionals and treatments are defined as conventional care
within the public healthcare system in one country and as
CAM in other countries, depending on national regulation
[30–34]. The CAMbrella data have so far been analyzed
from different angles with respect to risk theories and risk
understandings. Wiesener [33] discusses whether CAM
regulation in Europe is in accordance with current risk
theories related to health governance and patient safety,
whilst Wiesener and colleagues [34] discuss possible risk
understandings among European health policy-makers on
a structural level. In this article, we explore and discuss
differing risk understandings on an individual level among
persons seeking healthcare, healthcare professionals,
CAM providers and representatives for the health
authorities. We combine the perspectives and findings
from our earlier studies in an analysis of differing risk un-
derstandings and their possible implications for patient
safety across structural and individual levels of communi-
cation and decision-making.
Aims and research questions
The overall aim of this article is to contribute to an
awareness of the possible existence and importance of
differing risk understandings with regard to patients’ use
of CAM, both in clinical encounters in public healthcare
and among individuals involved in health policy-making
across European countries. Such knowledge may be of
vital importance to be able to fully grasp and handle
risks associated with use of CAM on an individual and
structural level, both within national public healthcare
systems and cross-border.
The research questions are:
1. How is “risk” understood by individuals involved in
health policy-making and clinical encounters across
the two included studies?
2. How might these risk understandings influence
different stakeholders’ decision-making, risk com-
munication, and health policy-making with regard
to CAM use within and across European countries?
Methods
Material
This empirical analysis was based on two already intro-
duced qualitative studies with materials that include differ-
ent stakeholders’ perspectives on risk understandings and
patient safety [14, 15, 28–34]. The studies are inter-related
because they had open-ended, qualitative designs and data
turned out to include information on different stake-
holders’ understandings and handling of risks associated
with the use of CAM. In the EU-study CAMbrella, docu-
ments and personal communications dealing with legisla-
tion and regulation of CAM were collected from the
European Union (EU) and from 39 European countries
[30–32]. The general legal and regulatory status of CAM
on the first and second national legal level was reviewed,
including supervision and reimbursement. Data on the
regulation of 12 CAM treatment modalities and CAM
providers/professions in each of the 39 countries were also
collected. The material is extensive and consists of a great
number of legal documents and statements from official
web-sites and government documents dealing with regula-
tion. Personal communications consist of answers to ques-
tionnaires and interviews, in addition to notes and
minutes from telephone conversations, emails, personal
meetings and conference discussions. Persons included in
personal communications were representatives for
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Ministries of health, law and education, governmental rep-
resentatives, CAM providers, members of CAM associa-
tions, and researchers in the 39 included countries (for
further information, see 30–34). In the study on under-
standings of benefits and risks associated with the use of
CAM, in-depth interviews with 31 Norwegian and Danish
patients who were CAM users and diagnosed with cancer
(19 participants) or multiple sclerosis (12 participants)
and 12 of their doctors (5 physicians, 4 oncologists, 3 neu-
rologists) were conducted [14, 15, 28, 29]. The main
themes in the CAM user interviews were personal history,
being a patient within the public health-care system, expe-
riences from doctor–CAM user communication, and rea-
sons for the choice and use of CAM including
understandings of risk and risk assessment. In the inter-
views with doctors, the main issues concerned experiences
with patients’ CAM use, risk understandings associated
with conventional medicine and CAM, and doctor-CAM
user communication. The interviews lasted from 45 to
150min, and were conducted by the first author and an
experienced research assistant [14, 15, 28, 29].
Methods
In-depth individual interviews and document analysis
were selected as research methods in the two included
studies. These qualitative methods were chosen because
we explored under-researched and experience-based is-
sues of which there were little previous knowledge [35].
It has been strongly argued that CAM research demands
methodological approaches that incorporate subjectivity,
everyday life, environment, and the complexity of mod-
ern health-care systems. The validity of qualitative meth-
odology has thus been identified as fundamental to
understanding and describing the philosophical basis,
key treatment components, and contextual frameworks
of CAM use and CAM modalities [24–26], here includ-
ing risk understandings and health policy-making.
We determined qualitative content analysis to be a suit-
able analytical approach, defined as a systematic classifica-
tion process and identifying different themes or patterns,
and used to interpret meaning from the content of text data
[36]. Furthermore, we compared and integrated the original
findings from the two different, yet inter-related studies.
Through the construction of a case history, the findings
were further described and analyzed. Thus, the technique
had an interpretive, rather than aggregating intent, in con-
trast to meta-analysis of quantitative studies which is aggre-
gative and reduces data to a single unit [37, 38]. Because
the authors themselves have conducted the included stud-
ies, and also have been working together in a
multi-disciplinary research group focusing on patient safety,
we claim that the interpretations in the comparison of
study results acknowledge the intent and philosophical
basis for each of the original studies [38]. In a final
analytical step, the authors developed a table of questions
to ask in settings possibly involving differing risk under-
standings that may influence patient safety nationally and
cross-border. We have chosen to present the main themes
and patterns revealed across the two studies as the con-
structed case Sara instead of presenting an analysis based
on quotations from interviews and personal communica-
tions. This approach was chosen because a case can
visualize the important contextual and processual aspects
of the empirical material with respect to our research ques-
tions [39, 40]. We thus demonstrate the importance of ac-
knowledging stakeholders’ differing risk understandings in
regulation/health policy-making and clinical settings involv-
ing use of, and/or discussion about the use of CAM, within
a real-life context. Constructed cases are often used as ex-
ploratory, descriptive and explanatory research and to gen-
erate theory and initiate change in practice and education
[38, 39]. The case Sara is based on the experiences and re-
flections of a real cancer patient participating in one of our
studies among CAM users and their medical doctors, and
combined with important empirical patterns revealed in
multiple individual interviews with different stakeholders in
the CAMbrella study [14, 15, 28–34]. Some quotations
from the in-depth interview with this patient are included
in the case presentation, however with several changes
made to include important information from the CAM-
brella study. In this constructed case, we have also added
use of acupuncture in Norway and abroad to the treat-
ments Sara actually used, because the regulation of acu-
puncture in Europe is a striking example of disharmonized
regulation in European health care [30, 32, 34].
Ethics, consents and permissions
The interview study was approved by the Regional Com-
mittee for Medical and Health Research Ethics North (P
REK NORD 28/2005), and the Norwegian Centre for Re-
search Data (project number 13409). In the CAMbrella
project, interviewees were asked to confirm the author’s
comprehension of their answers, and if cited, to confirm
the use of their answers with reference to their names,
position and/or rank [30].
Results
When comparing the two studies, it was not possible to
identify a “CAM treatment safety system” based on clinical
and regulation standards, professional training, definitions
and terminology. In a secondary analysis of the CAMbrella
material, we found that different government and public
sector employees within and between countries answered
the same questions very differently. We found the same
patterns in the answers from providers either representing
CAM associations or themselves as CAM health profes-
sionals or providers. We found that, even within the same
ministry, government department, institution or hospital,
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descriptions and specifications related to providers, treat-
ment standards and regulations were interpreted differently
among the involved persons. In legislation and legal pre-
paratory work it is thus difficult to settle if, and eventually
how, individual incoherent risk understandings have been
taken into consideration. Arguments for and against CAM
regulation, in a risk and patient safety perspective, are very
difficult to structure and compare. In a secondary analysis
of the interviews with CAM users and medical doctors, the
same lack of common risk understandings and regulatory
systems was identified. The CAM users found CAM to be
“green”, “natural” and “safe”, while their medical doctors
found no evidence to trust CAM treatments. Neither the
CAM users nor the medical doctors had been previously
asked about their risk understandings, and the rather fun-
damental gaps between risk understandings related to
CAM use in these two groups negatively influenced risk
communication. Different stakeholders’ unclear and differ-
ing risk understandings across the two studies seemed to
be influenced by a variety of factors involving education, in-
dividual experience from professional and personal settings,
cultural beliefs, social practices, attitudes, and values. In the
following constructed patient/CAM user case, we further
demonstrate these results on different aspects of gaps in
risk understandings and their possible consequences as re-
vealed across the two materials. The results are summa-
rized after the case presentation, as a basis for an in-depth
discussion of their possible implications.
“Then I went to a hospital abroad”: Sara’s cancer
trajectory in a European patient safety perspective
Sara is a nurse in her 50’s, with 30 years of experience
from working with cancer patients in Norwegian hospi-
tals. Soon after being diagnosed with breast cancer stage
II in 2010, she decided to combine conventional treat-
ment offered in the Norwegian public health-care system
with CAM treatments found outside this system. Her
decision was based on a personal knowledge basis con-
sisting of both experiences such as the observation of
dramatic, fatal cancer courses in her family and in hos-
pital settings, and scientific knowledge about adverse ef-
fects from conventional cancer therapies. Furthermore,
Sara was familiar with and believed in CAM therapies
after having taken an education in reflexology herself.
She experienced that her focus on bodily experiences
and personal efforts, which she found to be crucial for a
successful treatment of her cancer, was not accepted
within the Norwegian public health-care system.
Sara received surgery and suffered through a difficult
first period of chemotherapy that caused severe adverse
effects. After that, she perceived continued conventional
cancer treatment as a considerable risk to her health and
quality of life at that point of her cancer trajectory. She
collected a lot of information about treatment options,
and then decided to use different alternative therapies
provided by CAM practitioners. Sara explained:
I had faith that there are many roads to Rome… I
thought that CAM is natural and would not harm
me… Most people having had similar surgery
experience severe adverse effects. I didn’t want to
poison the body with chemotherapy and radiation. I
had good reason (based on knowledge of conventional
and alternative treatment options, authors’ comment)
to believe that I could reach a better goal without
continuing the conventional treatment at the moment.
After a period of self–care, Sara decided to visit a hos-
pital in another European country. In this hospital, can-
cer patients learned to manage their cancer from a
therapeutic perspective that included both body and
mind. The hospital had Western medically educated
doctors and was part of the public health-care system in
the country where it was located. All treatments, such as
acupuncture and herbal medicine, were regulated within
the public health-care system. Despite this, Sara experi-
enced that the Norwegian hospital doctors were funda-
mentally skeptical to the medical skills of their foreign
colleagues, and the possible risks associated with the
treatments Sara wanted to use. Several of these treat-
ments were defined as CAM according to Norwegian le-
gislation. Among these treatments were herbal medicine
and a certain acupuncture treatment that Sara thought
would strengthen her immune system and thus possibly
enable her to receive chemotherapy in the Norwegian
hospital later on. According to Sara, the Norwegian doc-
tors were unwilling to discuss her treatment decisions.
They were fundamentally skeptical because they found
only limited scientific evidence for positive outcomes or
an acceptable level of risk associated with the treatments
Sara wanted to use. Based on information from the for-
eign hospital and the Internet, and discussions with
friends, Sara found that the CAM treatments were safe
and would have no negative influence on the conven-
tional cancer treatment she planned for in Norway when
she returned home. Sara eventually went to the hospital
abroad, and was very satisfied with the treatments, the
treatment philosophy and the health-care professionals
she met:
The treatments were very holistically oriented,
everything from diet and nutrition to focus on patients’
mental health status, stressful lives and so forth… The
doctors were all so nice and friendly and remembered
all the patients’ names…The same doctor visited me
every day, and I was told that I could ask to see her
anytime. When I told her about the skeptical
Norwegian doctors, she said, very friendly, that she
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thought their attitude would change over time towards
a more holistic medicine, based on natural products
and focus on mind, body and self-care.
According to Sara, she was not offered a check-up at
the Norwegian hospital after she returned home and she
has not received any conventional cancer treatment
since then. Sara still feels abandoned by the Norwegian
hospitals’ oncology department, but has established a
very well-functioning relationship with a general practi-
tioner in her village and relates to his medical advice.
Summary of results
By combining and comparing individual and structural per-
spectives on risk, CAM use and regulation, we have re-
vealed that there are underexplored gaps in risk
understandings among individuals involved in European
CAM regulation and legislation, and between CAM users
and their medical doctors. The constructed case Sara dem-
onstrates a lack of harmonized risk understandings between
health policy makers and health professionals in different
countries, and between both these groups of stakeholders
and Sara as a patient and CAM user. Furthermore, the case
demonstrates a lack of information and communication on
risk and patient safety associated with CAM use and
cross-border health care. Consequently, patients/CAM
users, public health-care providers, CAM providers, health
authorities and researchers may have insufficient informa-
tion to understand and assess risk in settings involving
CAM. On an individual level, this is a potential problem
between the public health-care system and the patient/
CAM user, e.g., if health professionals refuse to discuss
CAM use with a cancer patient or a patient/CAM user
who do not dare to raise the issue. Also on a structural
level, this case demonstrates possible gaps in risk under-
standings that might negatively influence patient safety and
the risk scenario for Sara. The CAM treatments she chose
to use were subject to rather different public regulation in
the two countries involved, and the claim, reimbursement
and supervision systems between the two countries differed
fundamentally. In some countries, CAM modalities and
providers are regulated with educational requirements,
treatment standards and ethics, within the same system as
conventional public health-care services. Interviewees from
these countries underlined that regulation is important to
be able to perform supervision of CAM providers, secure
patient’s claim rights, and control safety aspects like treat-
ment quality assessment and safety information to patients
like Sara.
Discussion
According to the EU Directive 2011/24/EU on the appli-
cation of patients’ rights in cross-border health care
[41], patients like Sara have the right to be informed. To
make it possible to provide and receive correct informa-
tion about different treatment options across national
borders, there has to be a common understanding of
facts, regulation and terminology on one hand, and
treatment and provider requirements on the other. Con-
sequently, we could ask; who “owns” the correct descrip-
tions of facts when there are few common
understandings of safety and risks issues among different
stakeholders such as Sara, the Norwegian hospital doc-
tors and the doctors working in the foreign hospital?
Regulation and educational background for CAM
providers in cross-border health care
In a first setting, Sara may receive acupuncture in the
Norwegian hospital, provided by an authorized, “regu-
lated” medical doctor or nurse. In another setting, Sara
chooses to use an acupuncturist outside the regulated
Norwegian public health-care system. The acupuncturist
will then have an unregulated, and often unknown,
training and capability of handling possible risks associ-
ated with the treatment. An important question is
whether Sara is less at risk when receiving acupuncture
treatment at the hospital by a “regulated” medical doctor
or nurse than she is when receiving acupuncture by the
“unregulated” acupuncturist? In Norway, this acupunc-
turist is probably a member of an established acupunc-
ture association. These associations have claims to their
members about medical education, acupuncture training
and ethics. Concerns have been raised about the quality
of acupuncture training among Norwegian nurses and
medical doctors who provide acupuncture within the
public health-care system [42]. However, if Sara receives
acupuncture within the public health-care system the
Norwegian authorities can support her with a legal basis
for compensation of possible health damages, reimburse-
ment of costs and supervision of the involved health
professionals. If Sara chooses the “unregulated” acu-
puncturist, she does not have these rights. In a third set-
ting, Sara decides to receive acupuncture in another
European country than Norway. Which country she
chooses to go to, may strongly influence her rights as a
patient. Acupuncture is regulated in 26 out of 39 Euro-
pean countries [30, 32], as shown at the updated CAM
regulation website from National Research Center in
Complementary and Alternative Medicine (NAFKAM)
in Fig. 1 based on data from 2017 [32].
When checking the details in each country, we find
that none have similar legislation. Furthermore, we find
that in three countries, “acupuncturist” is a regulated
health profession, while in 23 countries “acupuncturist”
is not a regulated profession, only the acupuncture treat-
ment itself is regulated. The last 13 countries have no
specific acupuncture treatment regulation, but may be
covered by the general health regulation. In some of the
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European countries, only doctors may provide acupunc-
ture treatment. The educational level to be approved to
provide acupuncture differs from courses offered by an
acupuncture association (e.g., Cyprus) to 3–5 years of
university training (e.g., Hungary) [30, 32]. We know
that CAM users favor CAM providers that are govern-
mentally authorized health professionals [43]. However,
Sara will probably not know the qualification require-
ments for a medical doctor to get approval to practice
acupuncture, his/her actual training in acupuncture, the
reimbursement rights in the actual country or how to
make claims if the acupuncture treatment causes harm.
If a patient like Sara crosses borders between countries
to receive a treatment, both language, culture and other
contextual factors may make important information on
patient safety difficult to access and understand. Patients
who choose CAM treatments are thus often not able to
be “informed patients” in cross-border health care as de-
scribed in the EU Directive 2011/24/EU [41]. If Sara re-
ceives acupuncture treatment in Hungary, the provider
will probably be a medical doctor with an additional
acupuncture degree from a university. If she chooses to
Fig. 1 “Regulation of Acupuncture in Europe” depicted in Fig. 1 has been developed by the second author Wiesener, S and this updated version
has not been published before. The map is developed on the basis of an uncolored clip-art map of the European countries, retrieved from:
“Bruce Jones design Inc. 2006 - http://cam-regulation.org/en/acupuncture-map”. The clip-art map was purchased first time for use by NAFKAM in
the CAMbrella project
FP7-HEALTH-2009, GA No.241951. NAFKAM allows the authors to develop maps using this purchased clip-art
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receive acupuncture in Ireland, where CAM is unregu-
lated, the provider may be either a non-professional or a
health-care professional. As clearly demonstrated by
these examples, the situation is complex in several im-
portant aspects, which may all represent a possible
threat to patient safety for CAM users in national and
cross-border health-care settings.
Communication about risk and possible implications for
patient safety
Some patients, e.g., Sara, decide to delay or decline offers
of conventional treatment, and use CAM instead. In con-
cordance with Sara’s case, studies have revealed that such
treatment decisions often represent a huge challenge in risk
communication between doctors and cancer patients [14,
15, 28, 29, 44]. Their understandings of risks and benefits
associated with CAM and conventional cancer care are
often incompatible in situations where cancer patients
choose to delay or decline conventional medicine. These
patients challenge the rationality of medical advice and the
authority of oncology experts, and may be subject to risks
associated to several aspects of CAM use [13–16, 28, 29].
In worst cases, this may have fatal consequences. Studies of
clinical outcomes of decliners of conventional cancer care
have revealed that failure to comply with the public
health-care system and the recommended conventional
care led to increased risk of cancer progression and/or
death [45, 46]. If health professionals like those at the
Norwegian hospital refuse to discuss CAM use and
cross-border health care with their patients, this may nega-
tively influence the patients’/CAM users’ trust in public
health care, and may function as a push-factor for the pa-
tient/CAM user to delay or decline conventional treatment.
Although Sara wanted to use alternative treatments and
postpone chemotherapy and radiation, she really wanted to
uphold her relationship with the public health-care system.
This is the situation with most CAM users [14, 19–21]. It
signals that if the public health care wants to be trusted and
actually act person-centred [47], it is of crucial importance
to focus on well-functioning communication and increased
knowledge about CAM users’ perspectives on benefits and
risks associated with the use of CAM and conventional
treatment [13, 14, 20–24, 48, 49].
The importance of acknowledging differing risk
understandings
As noticed in the introduction, the ontological status of
risk is heavily debated within the social sciences [1, 2, 22,
23, 27]. Approaching risk from various methodological
perspectives is important also in medical discourses as
there may exist a “…significant problem with using
epidemiological risk assessment, [which] is that risk is
reduced to a statistical measure that does not take into
account the attitudes or risk-taking behaviors of human
beings” ([22], p. 66). Based on the comparison of the stud-
ies under investigation in this article, we argue that this ar-
gument raised with regard to studies of risk in
conventional medicine and public health care may be even
more relevant for measurement and communication of
risks associated with the use of CAM. This does not mean
that CAM treatments necessarily are associated with
higher levels of risk than conventional treatments. Our ar-
gument is that the use of CAM, in a risk perspective, is
linked to uncertainty caused by factors like gaps in risk
understandings among different stakeholders, disharmo-
nized regulation across countries, lack of scientific evi-
dence and insufficient communication. Thus, risk
definitions related to the use of CAM should include ele-
ments of uncertainty and subjectivity, as argued in the
introduction [1, 2, 22, 23, 27]. This study and our previous
studies have brought to attention a number of questions
and challenges regarding risk, CAM use and regulation.
We thus call for a comprehensive and extended under-
standing of risk factors associated with the use and regula-
tion of CAM. To develop more comprehensive risk
understandings across stakeholders, national borders and
treatment contexts, we have transformed the findings re-
vealed in this study into questions to ask in various prac-
tical settings.
Introducing questions to ask for policymakers, in clinical
settings and in risk research that incorporate patients’
use of CAM
To transform the findings of this study into practical set-
tings and contribute to more comprehensive risk under-
standings in regulation, clinical practice and research
involving European patients’ use of CAM, we hereby
introduce four sets of relevant questions to ask in differ-
ent settings involving various stakeholders (Table 1).
These sets of questions do of course not cover all situa-
tions, but may function as a starting point that can be
further developed to fit specific settings involving risk
understandings and risk definitions.
Conclusion: we must confront the question “What
is risk?”
Many citizens in European countries combine conventional
treatment with CAM, and it is thus of crucial importance
to acknowledge the possible existence and implications of
differing risk understandings across stakeholders and coun-
tries. By combining and comparing individual and struc-
tural perspectives on risk, CAM use and regulation, this
study has demonstrated that different stakeholders may
understand and handle risk very differently. We argue that
this situation may have a negative and so far underesti-
mated influence on patient safety for European CAM users.
Any attempt to regulate, communicate about or study risk
in CAM should thus confront the question “What is risk?”.
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The suggested key questions in Table 1 may contribute to
operationalize this fundamental question in different set-
tings. In health care policy-making, answers to this question
may strongly influence public health care regulation. In
clinical practice, such answers may represent new know-
ledge that may contribute to better communication and im-
proved patient safety for CAM users. In research contexts,
answers to this question may have implications with respect
to research questions, methodology, what aspects of risk
that are revealed, and the interpretation of study results.
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Table 1 Key questions to ask for policymakers, in clinical settings and in risk research that incorporate patients’ use of CAM
Settings Questions
Regulation - the policy-
makers perspective
• Which decision factors (like research, efficacy and patient safety elements) is the national regulation of CAM based on?
• How should scientific evidence on direct and indirect risk factors influence regulation of the specific CAM modality?
• Which provider training and treatment requirements will strengthen the safety for CAM users/patients?
• How may a planned regulation of CAM providers and treatments increase patient safety?
• How can more harmonized and integrated regulation of conventional medicine and CAM result in increased patient safety?
• How should we emphasize safety aspects of European regulation on CAM when deciding new CAM regulation on
a national level?




• How does this CAM user understand risks associated with conventional treatment? Why?
• How does this CAM user understand risks associated with CAM/specific CAM treatments? Why?
• How do I myself as a health-care provider understand risk associated with CAM and conventional treatment?
• Do my risk understandings differ from those of the patient in front of me?
• How can I best communicate important risk information to this patient?
Clinical settings–
patient perspective
• How do I as a patient perceive my personal risk associated with the use of the CAM I want to use?
• How do I as a patient perceive my personal risk associated with the use of the recommended conventional treatment?
• How can I best communicate my interest in CAM to medical doctors and nurses in public health care?
• What does this doctor know about CAM?
• What training does this CAM provider have?
• What does this CAM provider know about medicine/conventional treatment?
• Where can I find trustworthy information about CAM treatments and CAM providers?
• Is the CAM treatment I want to use associated with any possible risks?
• Is the conventional treatment I use associated with any possible risks?
• Are there any known risks associated with the combination of the conventional and the CAM treatment I want to use?
• How can I deal with possible risks?
Risk research • Does the risk study we are planning include an understanding of risk as an objective or a subjective phenomenon?
• Have we actually defined the concept of risk in our study?
• Would another risk understanding/definition influence the study in terms of research questions, methodology,
and interpretation of results?
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